Multi-Cancer Early Detection (MCED)
A blood-based screening approach that looks for cancer-associated signals in circulating cell-free DNA. MCED may complement established screening, but it is not a diagnostic test and it does not rule out cancer when negative.
This page is longer and more cautious than most descriptions of these tests. That is deliberate: MCED is genuinely promising, genuinely unproven for mortality benefit, and genuinely capable of setting off a chain of investigations. All three facts belong in the decision.
A screening signal, not a cancer diagnosis
Multi-cancer early detection tests analyse patterns in circulating cell-free DNA, such as methylation or other cancer-associated molecular signals. Depending on the assay, the report may indicate whether a cancer signal was detected and may estimate a likely tissue of origin.
A positive screening result requires further medical assessment and targeted diagnostic testing. A negative result does not exclude cancer, because sensitivity varies by cancer type, tumour biology and stage.
The underlying biology is straightforward enough. All cells shed fragments of DNA into the bloodstream as they die, and tumour cells shed fragments carrying distinctive chemical marks — particularly patterns of methylation that differ from healthy tissue. An MCED assay looks for those patterns among a very large background of normal DNA. The difficulty is precisely that the signal is small, especially when a tumour is small.
Age- and risk-appropriate tests such as mammography, cervical screening, colorectal screening and other guideline-based investigations remain important even when an MCED result is negative.
How the test fits into a screening plan
1. Risk review
We review age, personal and family history, smoking exposure, symptoms, previous screening and relevant medical conditions before discussing whether MCED adds useful information.
2. Blood collection
A blood sample is collected and sent to the relevant laboratory for molecular analysis. Turnaround time depends on the assay and laboratory.
3. Results and next steps
Results are interpreted in clinical context. A cancer signal does not confirm cancer; targeted imaging, endoscopy, biopsy or specialist referral may be needed.
Specificity and sensitivity are not the same thing
Specificity
Many MCED assays are designed for high specificity, meaning false-positive screening signals are relatively uncommon. High specificity is useful, but it does not remove the need for confirmatory investigations after a positive result.
Sensitivity
Sensitivity is variable and is generally lower for some early-stage cancers. An MCED test can therefore miss cancer. The performance of one assay should not be assumed to apply to another.
Tissue-of-origin prediction
Some assays estimate where a cancer signal may have originated. This can help direct follow-up, but it is still a prediction and not proof of the cancer site.
Population evidence
MCED is a rapidly developing field. Research is ongoing to determine how screening programmes affect stage at diagnosis, downstream investigations, overdiagnosis and ultimately cancer-specific mortality.
The number that matters most is the one least often quoted
Marketing tends to lead with specificity, because it sounds reassuring. The figure that actually determines what a positive result means to you is the positive predictive value — the probability that a person with a positive test genuinely has cancer. That depends not only on the test but on how common cancer is in the population being tested.
A worked example makes this concrete. The numbers below are deliberately simplified and illustrative rather than drawn from any particular product, but the arithmetic is the point:
| Assumption | Illustrative figure |
|---|---|
| People screened | 10,000 |
| Who genuinely have an undetected cancer | 50 (0.5%) |
| Test sensitivity | 50% — so 25 of those 50 are detected |
| Test specificity | 99% — so about 100 of the 9,950 without cancer test positive |
| Total positive results | 125 |
| Of whom actually have cancer | 25 — that is 1 in 5 |
In that illustration, a test with excellent-sounding 99% specificity still produces four false alarms for every true finding — and each of those 100 people faces investigation for a cancer they do not have. Meanwhile 25 people with cancer were reassured by a negative result. Neither of those facts makes the test useless. Both of them make it a decision rather than an obvious good.
The same arithmetic explains why these tests perform better in higher-risk groups. Where the underlying probability of cancer is greater, a positive result is more likely to be true, which is one reason risk assessment before testing matters more than it might appear.
What the evidence does and does not yet show
Being straightforward about this matters, because MCED is marketed with considerable confidence. What has been demonstrated is that these assays can detect cancer signals in blood, that specificity can be high, and that tissue-of-origin prediction is often reasonably accurate. Those are real achievements.
What has not yet been demonstrated is the outcome that ultimately justifies any screening test: that screening a general population with MCED causes fewer people to die of cancer. Large randomised trials designed to answer that question have been running, including a substantial NHS-led study in the United Kingdom, but the results needed to establish mortality benefit take years to mature.
This is not a technicality. Screening history contains several examples of tests that reliably found more cancer without helping people live longer, because they detected disease that would never have caused harm, or detected aggressive disease no earlier than it would have presented anyway. Finding cancer earlier and reducing deaths from cancer are related but genuinely different things.
Overdiagnosis
Some detected cancers would never have caused symptoms in a person's lifetime. Treating them carries real harm with no benefit, and there is often no way to know in advance which ones they are.
The diagnostic cascade
A positive signal can lead to imaging, endoscopy and biopsy, each with its own cost, discomfort and small risk — sometimes ending with no cancer found.
False reassurance
The most avoidable harm is a negative result leading someone to skip guideline screening or ignore a new symptom.
Who might discuss MCED with a doctor?
Adults seeking broader screening
Particularly when standard screening covers only a limited number of cancer types.
People with increased risk
Family history, previous cancer, smoking history or other factors may justify a more detailed screening discussion, though MCED is not a substitute for genetics or specialist surveillance.
People without concerning symptoms
MCED is primarily a screening concept. New unexplained weight loss, bleeding, persistent pain, a new lump or other concerning symptoms require diagnostic evaluation rather than relying on a screening blood test.
Those comfortable with uncertainty
Anyone who would find an ambiguous or false-positive result intolerable should think carefully before testing.
Those who would act on a result
The test is only worth doing if you would accept the investigations a positive signal triggers.
Those already up to date
MCED makes most sense as an addition to guideline screening, not as a replacement for screening someone has been avoiding.
| Your situation | Is MCED the right step? |
|---|---|
| You have a new lump, bleeding, unexplained weight loss or persistent symptoms | No — you need diagnostic evaluation, not screening. A negative screen would be dangerously misleading. |
| You are overdue for mammography, cervical or colorectal screening | Do those first. They have proven mortality benefit; MCED does not yet. |
| You have a strong family history suggesting an inherited syndrome | Genetic assessment and specialist surveillance come first. |
| You are up to date on screening and want broader coverage | A reasonable discussion, with the limitations above understood. |
| You would decline follow-up investigation of a positive result | Then testing is not advisable. |
| You are already anxious about cancer | Worth discussing carefully — testing can relieve or amplify anxiety, and a false positive is a difficult experience. |
What happens after a positive result?
A cancer-signal-detected result is not equivalent to a diagnosis. Follow-up is guided by the predicted tissue of origin, clinical history and examination. This may include blood tests, ultrasound, CT/MRI, endoscopy or referral to an appropriate specialist. Tissue diagnosis with biopsy is often required before cancer treatment decisions are made.
Because follow-up can involve anxiety, cost and additional testing, the decision to undergo MCED should include a discussion of these downstream implications before testing.
Two further scenarios are worth anticipating. Sometimes investigations find nothing, which leaves an unresolved positive signal and a decision about whether to repeat imaging later — a state some people find harder than a definite answer either way. And sometimes investigations find an incidental abnormality unrelated to the original signal, which then requires its own workup. Neither is a failure of the test; both are ordinary consequences of looking.
MCED testing is generally self-funded, and the investigations that follow a positive result are usually additional. Anyone considering the test should understand the potential total cost, not only the price of the blood test itself.
Frequently asked questions
Can MCED detect every cancer?
No. The number of cancer types and performance varies by assay, and some cancers or early-stage cancers may not release a detectable signal.
Does a negative result mean I do not have cancer?
No. A negative result lowers concern only within the limitations of that assay. It cannot exclude cancer and should not delay evaluation of symptoms.
Can it replace mammograms, Pap/HPV testing or colon cancer screening?
No. Established screening should continue according to age, sex, risk and local clinical guidance unless your doctor advises otherwise.
What if the test detects a cancer signal?
You will need confirmatory evaluation. The next investigation depends on the estimated tissue of origin and your clinical risk profile.
Is MCED suitable for everyone?
Not necessarily. Testing is best considered after a doctor reviews your age, risk factors, current screening and whether you have symptoms that require diagnostic investigation instead.
If specificity is 99%, why might a positive result still be wrong?
Because cancer is uncommon in a screened population. When few people tested actually have cancer, even a small false-positive rate produces more false alarms than true findings — which is why positive predictive value matters more than specificity alone.
Has MCED been shown to save lives?
Not yet. These assays can detect cancer signals, but large randomised trials assessing whether population screening reduces cancer deaths are still maturing. Finding cancer earlier and reducing deaths are related but different things.
What is overdiagnosis?
Detecting a cancer that would never have caused symptoms in a person's lifetime. Treating it carries real harm with no benefit, and there is often no way to identify such cases in advance.
What if investigations find nothing after a positive signal?
That happens, and it leaves an unresolved result with a decision about repeat imaging later. Some people find that ambiguity harder than a definite answer.
Could investigations find something unrelated?
Yes. Incidental findings requiring their own workup are an ordinary consequence of imaging, not a failure of the test.
Should I have this instead of my colonoscopy?
No. Colorectal screening has demonstrated mortality benefit, and MCED does not yet. Using it as a substitute for proven screening is the most avoidable harm associated with these tests.
I have symptoms — should I take this test first?
No. Symptoms need diagnostic evaluation, and a negative screening result in that situation would be dangerously misleading.
Does it work better in some people than others?
Yes. Where the underlying likelihood of cancer is higher, a positive result is more likely to be genuine, which is why risk assessment before testing matters.
How accurate is the tissue-of-origin prediction?
Often reasonably accurate and useful for directing follow-up, but it remains a prediction rather than proof of the cancer site.
How often would I repeat it?
There is no established interval, partly because the evidence needed to define one does not yet exist. Any repeat schedule should be a considered discussion rather than an automatic annual booking.
What does it cost overall?
The blood test is generally self-funded, and follow-up investigations after a positive result are usually additional. Understanding the potential total cost is part of informed consent.
Will my insurance cover it?
Screening tests of this kind are frequently not covered. Check directly with your insurer, including whether follow-up investigations prompted by a screening result would be covered.
Is it the same as a genetic test for cancer risk?
No. Genetic testing assesses inherited predisposition; MCED looks for signals from cancer that may already be present. They answer different questions.
What is the single most important thing to understand?
That a negative result does not mean you are cancer-free, and a positive result does not mean you have cancer. It is a signal that changes probability, not a verdict.
Where is Aquila Medical Center?
Aquila Medical Center is at 160 Robinson Road, #05-01 SBF Centre Medical Suites, Singapore 068914, in the CBD, a short walk from Tanjong Pagar, Shenton Way and Telok Ayer MRT stations.
Selected references
- Sensitivity and Specificity. StatPearls, NCBI Bookshelf.
- Positive and Negative Predictive Value. StatPearls, NCBI Bookshelf.
- US National Cancer Institute. Multi-cancer detection tests.
- US National Cancer Institute. Overdiagnosis in cancer screening.
- Singapore HealthHub. Screen for Life national screening programme.
This page is educational and does not replace an individual medical consultation. MCED tests differ by assay, are not diagnostic, and have not yet been shown in completed randomised trials to reduce cancer mortality. The worked example above is illustrative arithmetic, not the performance of any specific product. Content reviewed by the medical team at Aquila Medical Center, Singapore. Last reviewed: 26 August 2026.
A considered decision, not a routine add-on
Aquila Medical Center discusses MCED in the context of your age, risk profile, existing screening and what you would want to do with each possible result — rather than adding it automatically to a screening package.
Where the more valuable step is completing the screening you are already due, we will say so. Aquila Medical Center, 160 Robinson Road, #05-01 SBF Centre Medical Suites, Singapore 068914.